PAR

4.00%

39.0¢

PARADIGM BIOPHARMACEUTICALS LIMITED..

Market Cap $151.8M Add to my watchlist

Healthcare Biotechnology

Paradigm Biopharmaceuticals Limited is a late-stage drug development company. The Company... Paradigm Biopharmaceuticals Limited is a late-stage drug development company. The Company is engaged in discovering, developing, and delivering pharmaceutical therapies. It is focused on the development of injectable pentosan polysulfate sodium (iPPS/PPS) for the treatment of osteoarthritis (OA) and mucopolysaccharidosis (MPS). Pentosan polysulfate sodium is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). It develops PPS under the brand name Zilosul. PPS also inhibits the synthesis of the metalloproteinase, MMP-3 (Troeberg) involved in degrading cartilage. PPS also include treatment of joint function, mobility, and pain in patients with MPS; treating alphavirus-induced arthralgia (such as Ross River virus and Chikungunya); chronic heart failure (HF) and acute respiratory distress syndrome (ARDS).More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Latest Threads

Tag

Subject

PAR

The possible funding pathways...

12:22

1.1K

12:22

Last post bobsee

1.1K

PAR

2025 partnership

27/12/24

1.3K

27/12/24

Last post asx11

1.3K

PAR

Competition???

27/12/24

34K

27/12/24

Last post JamesTas

34K

PAR

The Dynamic Duo

27/12/24

3.4K

27/12/24

Last post Mozzarc

3.4K

PAR

compounding chemist

26/12/24

3.8K

26/12/24

Last post bandos2000

3.8K

PAR

Chart

73 74 75

25/12/24

4.4K

3.9M

25/12/24

Last post poolboy

4.4K

3.9M

PAR

Ann: PAR Capital Raising Presentation

22/12/24

108

37K

22/12/24

Last post 39KP

108

37K

PAR

Where are we on a deal?

2 3 4

21/12/24

232

85K

21/12/24

Last post JamesTas

232

85K

See All Discussions

Timeline

Notification regarding unquoted securities - PAR
20 Dec 15:25	Share

Cleansing Notice
13 Dec 08:29	Share

Application for quotation of securities - PAR
13 Dec 08:24	Share

PAR Capital Raising Presentation
09 Dec 09:24	Share

Proposed issue of securities - PAR
09 Dec 09:21	Share

Successful Completion of $16M Placement for Phase 3
09 Dec 09:21	Share

Change of Director's Interest Notice
05 Dec 17:25	Share

Change of Director's Interest Notice
05 Dec 17:12	Share

Trading Halt
05 Dec 08:45	Share

Appendix 3H - Notification of cessation of securities
05 Dec 08:36	Share

Appendix 2A
04 Dec 17:04	Share

Paradigm to Proceed with Phase 3 Knee OA Trial
28 Nov 08:33	Share

Response to ASX Price Query
25 Nov 15:45	Share

Change of Director's Interest Notice
21 Nov 14:45	Share

Notification of cessation of securities - PAR
21 Nov 14:35	Share

Final Director's Interest Notice
20 Nov 17:42	Share

Dr. Skerrett Steps Down from Board Following AGM
20 Nov 16:56	Share

Results of Meeting
19 Nov 17:58	Share

2024 Chairman Address and AGM Presentation
19 Nov 10:05	Share

Quarterly Activities/Appendix 4C Cash Flow Report
31 Oct 08:32	Share

Phase 3 Protocol Submission to US FDA
31 Oct 08:20	Share

Proposed issue of securities - PAR
24 Oct 08:41	Share

Change of Director's Interest Notice
23 Oct 18:50	Share

Change of Director's Interest Notice
23 Oct 18:49	Share

Notification of cessation of securities - PAR
22 Oct 20:28	Share

Paradigm Investor Update
21 Oct 09:09	Share

Notice of Annual General Meeting/Proxy Form
18 Oct 13:46	Share

Change of Director's Interest Notice
16 Oct 15:26	Share

Change of Director's Interest Notice
16 Oct 15:24	Share

Ceasing to be a substantial holder
26 Sep 17:16	Share

View More

(20min delay)
Last 39.0¢		Change 0.015(4.00%)		Mkt cap ! $151.8M

Open	High	Low	Value	Volume
38.0¢	41.0¢	38.0¢	$517.5K	1.298M

Buyers (Bids)

No.	Vol.	Price($)
4	72063	39.0¢

Sellers (Offers)

Price($)	Vol.	No.
40.0¢	147522	3

View Market Depth

No.	Vol.	Price($)
1	50000	0.390
5	135234	0.385
7	141188	0.380
8	244327	0.375
9	107128	0.370

Price($)	Vol.	No.
0.400	87522	2
0.405	100000	1
0.410	50000	1
0.415	57941	2
0.420	91000	1

Last trade - 16.10pm 27/12/2024 (20 minute delay)

PAR (ASX) Chart

PARADIGM BIOPHARMACEUTICALS LIMITED..

Corporate Spotlight
Not Yet Available

Latest Threads

Timeline

Featured News

Latest Articles

FDA hands Paradigm Biopharma guidance to re-jig phase 3 osteo trial – or is it a delay?

Paradigm has confirmed it will use a twice weekly dosage of 2mg/kg injectable pentosan polysulfate sodium in its Phase 3 trial.

Paradigm Biopharma on track to US Phase III osteo program

Paradigm Biopharma has announced its completion of a submission to the US FDA to progress to Phase III of its osteoarthritis 'program.'

Paradigm Biopharma tests show reverse knee degradation in osteoarthritis patients

Paradigm Biopharma (ASX:PAR), which is investigating the use of iPPS in osteoarthritis, reported that patients have experienced knee cartilage regrowth.

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News

PARADIGM BIOPHARMACEUTICALS LIMITED..

Corporate SpotlightNot Yet Available

Latest Threads

Timeline

Featured News

Latest Articles

FDA hands Paradigm Biopharma guidance to re-jig phase 3 osteo trial – or is it a delay?

Paradigm has confirmed it will use a twice weekly dosage of 2mg/kg injectable pentosan polysulfate sodium in its Phase 3 trial.

Paradigm Biopharma on track to US Phase III osteo program

Paradigm Biopharma has announced its completion of a submission to the US FDA to progress to Phase III of its osteoarthritis 'program.'

Paradigm Biopharma tests show reverse knee degradation in osteoarthritis patients

Paradigm Biopharma (ASX:PAR), which is investigating the use of iPPS in osteoarthritis, reported that patients have experienced knee cartilage regrowth.

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News

Corporate Spotlight
Not Yet Available